Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Pitt Street Research Life Sciences Conference 2024
31 slides from Proteomics International Laboratories's conference presentation, Sep 19, 2024
Slide 1: ASX Release: Investor Presentation
ASX Release 19 September 2024 ASX code: PIQ Investor Presentation Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to attendees at the Pitt Street Research Life Sciences
Slide 2: Pitt Street Research Life Sciences Conference Investor Presentation
ASX: PIQ Proteomics International LABORATORIES LTD Pitt Street Research Life Sciences Conference Investor Presentation 19 September 2024 Dr. Richard Lipscombe Managing Director 1
Slide 3: Disclaimer
Disclaimer ASX: PIQ This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in
Slide 4: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd ASX: PIQ A medical technology company at the forefront of predictive diagnostics and precision medicine Three key focus tests driven by a proprietary platform technology: • In commercialisation for predicting the onset of chronic kidney disease in type 2 and
Slide 5: Corporate Overview
Corporate Overview ASX: PIQ Corporate Snapshot Financial and Corporate ASX code PIQ Market Capitalisation A$78m • Top 40 Shareholders hold 53% Cash (30 June 2024) (+ R&D Tax Incentive ~$2m H1 FY25) ~A$6.6m • Directors are highly aligned with shareholders holding 14% Share Price (17 September 2024) A
Slide 6: Science Proven – Commercialisation Underway
Science Proven – Commercialisation Underway ASX: PIQ Over 20 years R&D experience New, cost-effective routes to market resulting in deep pipeline • Pandemic has changed the landscape: • 3 highly accurate tests middle-man can now be cut out commercialisation ready • Allows PIQ and their partners to g
Slide 7: The Problem: Target Populations for DKD, Endo and Eso
The Problem: Target Populations for DKD, Endo and Eso ASX: PIQ 10.5% of global adult population 1 in 9 women have 1-2% of western populations at risk – have diabetes endometriosis of Esophageal Cancer (Diagnosed by endoscopy with biopsy) 537m adults 378m 20-120m adults globally with women in eligibl
Slide 8: The Solution: Precision Medicine Targeting Unmet Needs
The Solution: Precision Medicine Targeting Unmet Needs ASX: PIQ Diabetic Kidney Disease Endometriosis Esophageal Cancer • 1-in-3 with diabetes currently • Potential target is all pre- • 1 in 20 cancer deaths have chronic kidney disease menopausal women globally worldwide due to esophageal • Promarke
Slide 9: Go-to-Market Pathways
Go-to-Market Pathways ASX: PIQ Traditional licensing model Laboratory runs test Promarker Hub via automated Laboratory processes pays PI a royalty Diagnostic laboratory per test licences the test Reagents are sold to Raw data submitted to calculate the laboratory ‘risk score’ and report sent to labo
Slide 10: PromarkerD Global Rollout – Key Highlights
PromarkerD Global Rollout – Key Highlights ASX: PIQ Intellectual Property Patents granted in all major jurisdictions - PromarkerD Patent family & Trademark covers 72% of the world’s diabetes patients CE Mark (EU) registration received for the PromarkerD Immunoassay IVD Regulatory US sales utilising
Slide 11: Launch Strategy for DTP
Launch Strategy for DTP ASX: PIQ Establishing first sales via direct-to-patient (DTP) builds product awareness and drives mainstream use and subsequent volume Step 1 Step 2 Step 3 Step 4 Engage patients Motivate patients Provide patient access Drive and Grow sales • Direct to consumer • Understand t
Slide 12: PromarkerD: Clinical Utility & Decision Impact
PromarkerD: Clinical Utility & Decision Impact ASX: PIQ Launch strategy supported by engagement with KOLs and primary care physicians Research indicates physicians would use PromarkerD to inform patient treatment decisions • 96% of physicians were likely to use PromarkerD test scores for clinical de
Slide 13: PromarkerD: Existing partnerships
PromarkerD: Existing partnerships ASX: PIQ Proteomics International is focused on supporting its partners to achieve first sales in each jurisdiction • PromarkerD is CE Mark registered in Europe Current Steps European Union • Detailed market assessments completed • Establish independent Reference La
Slide 14: Promarker – Platform Technology
Promarker – Platform Technology ASX: PIQ PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to create novel diagnostic tests 13
Slide 15: Pipeline of Precision Diagnostics
Pipeline of Precision Diagnostics ASX: PIQ Platform technology drives deep pipeline of novel diagnostic tests Further global potential in new markets • Promarker platform develops novel intellectual property • Targeting new diagnostic tests in areas of significant unmet need • Enormous markets and r
Slide 16: PromarkerEndo: Endometriosis
PromarkerEndo: Endometriosis ASX: PIQ World-first blood test ‘PromarkerEndo’ in late-stage development Clinical question – can a blood test distinguish between individuals who are: 1) healthy 2) symptomatic patients (pelvic pain but surgically-diagnosed absence of endometriosis) 3) endometriosis pat
Slide 17: PromarkerEso: Esophageal Cancer
PromarkerEso: Esophageal Cancer ASX: PIQ World-first blood test ‘PromarkerEso’ nearing commercialisation Clinical question – can a blood test distinguish between individuals who are: 1) healthy 2) esophageal adenocarcinoma (EAC) patients ➢ Only 50% of EAC patients report chronic acid reflux ➢ 90% of
Slide 18: Dx Pipeline: Oxidative Stress
Dx Pipeline: Oxidative Stress ASX: PIQ Potential world-first blood test in late-stage development What is Oxidative Stress? Targeting commercial use of OxiDx technology: • Oxidative stress occurs when the body’s ➢ Athletic monitoring tool for competition preparedness: antioxidant defences are overwh
Slide 19: Multiple Value Drivers in FY25
Multiple Value Drivers in FY25 ASX: PIQ Potential Share Price Catalysts throughout FY25 Milestone TARGET Qtr Dec Mar Jun Impact Exceptional Global Opportunity Commercial ➢ Disruptive, cutting-edge technology & proven in-house diagnostics platform First Sales PromarkerD in USA Initiate pathway to sig
Slide 20: Contact
Contact ASX: PIQ Dr Richard Lipscombe Dirk van Dissel Managing Director Investor Relations T: +61 8 9389 1992 Candour Advisory E: enquiries@proteomicsinternational.com T: +61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au ASX:PIQ 19
Slide 21: Supplemental
Supplemental ASX: PIQ 20
Slide 22: Board of Directors
Board of Directors ASX: PIQ Neville Gardiner BBus (Accounting and Business Law) (Curtin), Non-Executive Chair Seasoned finance professional with over 30 years’ experience providing corporate advice to Boards of public and private companies. South & He was Co-Founder and MD of Torridon Partners, an i
Slide 23: PromarkerD: Proactively Changing Renal Healthcare
Promarker D PROACTIVELY CHANGING RENAL HEALTHCARE A simple blood test for predicting diabetic kidney disease
Slide 24: PromarkerD: World Class Advisory Board
PromarkerD: World Class Advisory Board ASX: PIQ Proteomics International is supported by an international, highly acclaimed advisory board Professor Tim Davis MedSc, MB, W.Aust., DPhil Oxf., Professor Merlin Thomas MBChB, PhD, FRACP, FRACP, MRCP (UK) – Australia FAAHMS – Australia Consultant physici
Slide 25: Problem and Solution – Diabetic Kidney Disease
Problem and Solution – Diabetic Kidney Disease ASX: PIQ Current standard-of-care diagnostics • Existing tests (known as eGFR and ACR) can only detect chronic kidney disease once it is already present • Current standard-of-care tests cannot predict the onset Roadblock of diabetic kidney disease The P
Slide 26: PromarkerD - Patented in all Major Markets
PromarkerD - Patented in all Major Markets ASX: PIQ Diabetic Kidney Disease is becoming one of the largest burdens on healthcare systems globally Patent family & Trademark covers 72% of world’s diabetics1 45% Country Patent/Application No Patent Status No. Diabetics1 undiagnosed Australia 2011305050
Slide 27: PromarkerD – Simple Integration & Use
PromarkerD – Simple Integration & Use ASX: PIQ Blood sample drawn Biomarkers analysed Results generated by Results and intervention plan PromarkerD Hub software delivered Sample is drawn at clinic or Laboratory uses a standard Cloud based algorithm, the Clinician delivers results to patient patholog
Slide 28: PromarkerD – Results & Intervention
PromarkerD – Results & Intervention ASX: PIQ How PromarkerD results are delivered LOW RISK MODERATE RISK HIGH RISK RISK SCORE % 0 10 20 100 Prognostic 16% indicates a moderate risk of decline in kidney function* Risk Score Intervention Testing Regimen Low Risk • Standard diabetes management Test Ann
Slide 29: PromarkerD in the Clinic
PromarkerD in the Clinic ASX: PIQ Peer Reviewed Physician Support Outperforms Standard of Care PromarkerD tested on over 5,000 Survey of 400 Endocrinologists & • 857 community based patients tested for patients in 4-year clinical studies Primary Care Physicians (US based) existing DKD at baseline: 4
Slide 30: PromarkerD: Precision Medicine
PromarkerD: Precision Medicine ASX: PIQ The Need The Treatments The Utility There is a significant and growing need for Patients identified as high-risk of DKD by Complementary diagnostic intervention for diabetic kidney disease (DKD) PromarkerD now have multiple preventative Early diagnosis of DKD
Slide 31: PromarkerD: Key Publications
PromarkerD: Key Publications ASX: PIQ Prognostic Validation for Type 1 Davis TME, et al. Application of a validated prognostic protein biomarker test for renal decline in type 2 diabetes to type Diabetes 1 diabetes: The Fremantle Diabetes Study Phase II. ADC 2024. PromarkerD Demonstrates Benefit of
Proteomics International Laboratories — Pitt Street Research Life Sciences Conference 2024 on 6ix